Skip to main content
    N

    NRX Pharmaceuticals Inc (NRXP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.15
    -0.04 (-1.83%)

    Market Cap: $95.58M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    NRX Pharmaceuticals Inc (NRXP) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect NRX Pharmaceuticals (NRXP) to earn -$0.80 per share in the fiscal year ending Dec 31, 2026, on revenue of $5.61M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy4100.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    4

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 1281.3%.

    Fiscal year ending Dec 31, 2026
    -$0.80
    EPS consensus, revenue $5.61M
    Fiscal year ending Dec 31, 2027
    -$0.35
    EPS consensus, revenue $77.49M
    Next report
    Nov 17, 2026
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.80-$0.80 to -$0.801$5.61M$4.30M to $8.20M4
    Dec 31, 2027-$0.35-$0.35 to -$0.351$77.49M$6.00M to $228.50M4

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.23-$0.49 to -$0.117$2.62M$1.18M to $4.72M6

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Fiscal year ending Dec 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.36.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.80-$0.80-$0.80-$0.36-$0.36N/A
    Fiscal year ending Dec 31, 2027-$0.35-$0.35-$0.35$0.50$0.50N/A

    Frequently Asked Questions About NRXP

    What is the NRXP stock forecast?

    Consensus analyst estimates put NRX Pharmaceuticals's EPS at -$0.80 for the fiscal year ending Dec 31, 2026, on revenue of $5.61M. The consensus rating from 4 analysts is Buy.

    How do analysts rate NRXP stock?

    Of 4 analysts covering NRX Pharmaceuticals, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from NRXP next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.80, with estimates from -$0.80 to -$0.80 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.35, with estimates from -$0.35 to -$0.35 from 1 analyst.

    What revenue do analysts expect from NRX Pharmaceuticals next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $5.61M, with estimates from $4.30M to $8.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $77.49M, with estimates from $6.00M to $228.50M.

    How many analysts cover NRXP?

    4 analysts rate NRX Pharmaceuticals stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.